Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

Reply to "Mitochondrial DNA deletions discriminate affected from unaffected LRRK2 mutation carriers".

Bakshi R, Macklin EA, Schwarzschild MA.

Ann Neurol. 2019 Aug;86(2):326-327. doi: 10.1002/ana.25509. Epub 2019 Jun 12. No abstract available.

PMID:
31148194
2.

Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis.

Bjornevik K, Zhang Z, O'Reilly ÉJ, Berry JD, Clish CB, Deik A, Jeanfavre S, Kato I, Kelly RS, Kolonel LN, Liang L, Marchand LL, McCullough ML, Paganoni S, Pierce KA, Schwarzschild MA, Shadyab AH, Wactawski-Wende J, Wang DD, Wang Y, Manson JE, Ascherio A.

Neurology. 2019 Apr 30;92(18):e2089-e2100. doi: 10.1212/WNL.0000000000007401. Epub 2019 Mar 29.

PMID:
30926684
3.

Higher urate in LRRK2 mutation carriers resistant to Parkinson disease.

Bakshi R, Macklin EA, Logan R, Zorlu MM, Xia N, Crotty GF, Zhang E, Chen X, Ascherio A, Schwarzschild MA.

Ann Neurol. 2019 Apr;85(4):593-599. doi: 10.1002/ana.25436. Epub 2019 Mar 3.

PMID:
30761591
4.

Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.

Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A, Josephs KA, Fasano A, Morgante F, Savica R, Greenamyre JT, Cambi F, Yamasaki TR, Tanner CM, Gan-Or Z, Litvan I, Mata IF, Zabetian CP, Brundin P, Fernandez HH, Standaert DG, Kauffman MA, Schwarzschild MA, Sardi SP, Sherer T, Perry G, Leverenz JB.

Neurology. 2019 Feb 12;92(7):329-337. doi: 10.1212/WNL.0000000000006926.

PMID:
30745444
5.

Lifestyle and Parkinson's disease progression.

Ascherio A, Schwarzschild MA.

Mov Disord. 2019 Jan;34(1):7-8. doi: 10.1002/mds.27566. No abstract available.

PMID:
30653733
6.

Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis.

Nicholson K, Chan J, Macklin EA, Levine-Weinberg M, Breen C, Bakshi R, Grasso DL, Wills AM, Jahandideh S, Taylor AA, Beaulieu D, Ennist DL, Andronesi O, Ratai EM, Schwarzschild MA, Cudkowicz M, Paganoni S.

Ann Clin Transl Neurol. 2018 Oct 22;5(12):1522-1533. doi: 10.1002/acn3.671. eCollection 2018 Dec.

7.

Prediagnostic plasma branched-chain amino acids and the risk of amyotrophic lateral sclerosis.

Bjornevik K, O'Reilly ÉJ, Berry JD, Clish CB, Jeanfavre S, Kato I, Kolonel LN, Le Marchand L, McCullough ML, Paganoni S, Schwarzschild MA, Talbott EO, Wallace RB, Zhang Z, Manson JE, Ascherio A.

Neurology. 2019 Apr 30;92(18):e2081-e2088. doi: 10.1212/WNL.0000000000006669. Epub 2018 Nov 14.

PMID:
30429276
8.

Dissociation between urate and blood pressure in mice and in people with early Parkinson's disease.

Chen X, Umeh CC, Tainsh RE, Feng DD, Maguire M, Zuo F, Rahimian M, Logan R, Wang X, Ascherio A, Macklin EA, Buys ES, Schwarzschild MA; Parkinson Study Group (PSG) The Safety of Urate Elevation in Parkinson's Disease (SURE-PD) investigators.

EBioMedicine. 2018 Nov;37:259-268. doi: 10.1016/j.ebiom.2018.10.039. Epub 2018 Nov 8.

9.

Cardiovascular Safety of Febuxostat.

Bhattacharyya S, Macklin EA, Schwarzschild MA.

N Engl J Med. 2018 Oct 18;379(16):1582. doi: 10.1056/NEJMc1809736. No abstract available.

PMID:
30338966
10.

Appendectomy and risk of Parkinson's disease in two large prospective cohorts of men and women.

Palacios N, Hughes KC, Cereda E, Schwarzschild MA, Ascherio A.

Mov Disord. 2018 Sep;33(9):1492-1496. doi: 10.1002/mds.109. Epub 2018 Sep 14.

PMID:
30218460
11.

The association between restless legs syndrome and premotor symptoms of Parkinson's disease.

Iwaki H, Hughes KC, Gao X, Schwarzschild MA, Ascherio A.

J Neurol Sci. 2018 Nov 15;394:41-44. doi: 10.1016/j.jns.2018.08.028. Epub 2018 Sep 1.

PMID:
30212740
12.

Non-motor features of Parkinson's disease in a nested case-control study of US men.

Hughes KC, Gao X, Baker JM, Stephen C, Kim IY, Valeri L, Schwarzschild MA, Ascherio A.

J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1288-1295. doi: 10.1136/jnnp-2018-318275. Epub 2018 Aug 3.

PMID:
30076266
13.

Urate mitigates oxidative stress and motor neuron toxicity of astrocytes derived from ALS-linked SOD1G93A mutant mice.

Bakshi R, Xu Y, Mueller KA, Chen X, Granucci E, Paganoni S, Sadri-Vakili G, Schwarzschild MA.

Mol Cell Neurosci. 2018 Oct;92:12-16. doi: 10.1016/j.mcn.2018.06.002. Epub 2018 Jun 18.

PMID:
29928993
14.

Genetic variants related to urate and risk of Parkinson's disease.

Hughes KC, Gao X, O'Reilly EJ, Kim IY, Wang M, Weisskopf MG, Schwarzschild MA, Ascherio A.

Parkinsonism Relat Disord. 2018 Aug;53:4-9. doi: 10.1016/j.parkreldis.2018.04.031. Epub 2018 May 1.

15.

Integration of risk factors for Parkinson disease in 2 large longitudinal cohorts.

Kim IY, O'Reilly ÉJ, Hughes KC, Gao X, Schwarzschild MA, Hannan MT, Betensky RA, Ascherio A.

Neurology. 2018 May 8;90(19):e1646-e1653. doi: 10.1212/WNL.0000000000005473. Epub 2018 Apr 11.

16.

Bimolecular Fluorescence Complementation of Alpha-synuclein Demonstrates its Oligomerization with Dopaminergic Phenotype in Mice.

Cai W, Feng D, Schwarzschild MA, McLean PJ, Chen X.

EBioMedicine. 2018 Mar;29:13-22. doi: 10.1016/j.ebiom.2018.01.035. Epub 2018 Jan 31.

17.

Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk.

Kim IY, O'Reilly ÉJ, Hughes KC, Gao X, Schwarzschild MA, McCullough ML, Hannan MT, Betensky RA, Ascherio A.

Mov Disord. 2018 Mar;33(3):414-420. doi: 10.1002/mds.27279. Epub 2018 Jan 10.

18.

Pre-diagnostic plasma urate and the risk of amyotrophic lateral sclerosis.

O'Reilly ÉJ, Bjornevik K, Schwarzschild MA, McCullough ML, Kolonel LN, Le Marchand L, Manson JE, Ascherio A.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):194-200. doi: 10.1080/21678421.2017.1418005. Epub 2017 Dec 26.

19.

Differences in Parkinson's Disease Risk with Caffeine Intake and Postmenopausal Hormone Use.

Kim IY, O'Reilly ÉJ, Hughes KC, Gao X, Schwarzschild MA, Ascherio A.

J Parkinsons Dis. 2017;7(4):677-684. doi: 10.3233/JPD-171175.

PMID:
28984617
20.

Dietary antioxidants and Parkinson's disease.

Ascherio A, Schwarzschild MA.

Mov Disord. 2017 Nov;32(11):1501-1503. doi: 10.1002/mds.27194. Epub 2017 Oct 4. No abstract available.

PMID:
28976040
21.

Air Pollution and Risk of Parkinson's Disease in a Large Prospective Study of Men.

Palacios N, Fitzgerald KC, Hart JE, Weisskopf M, Schwarzschild MA, Ascherio A, Laden F.

Environ Health Perspect. 2017 Aug 18;125(8):087011. doi: 10.1289/EHP259.

22.

Targeting urate to reduce oxidative stress in Parkinson disease.

Crotty GF, Ascherio A, Schwarzschild MA.

Exp Neurol. 2017 Dec;298(Pt B):210-224. doi: 10.1016/j.expneurol.2017.06.017. Epub 2017 Jun 13. Review.

23.

Intake of dairy foods and risk of Parkinson disease.

Hughes KC, Gao X, Kim IY, Wang M, Weisskopf MG, Schwarzschild MA, Ascherio A.

Neurology. 2017 Jul 4;89(1):46-52. doi: 10.1212/WNL.0000000000004057. Epub 2017 Jun 8.

24.

KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients.

Quinti L, Dayalan Naidu S, Träger U, Chen X, Kegel-Gleason K, Llères D, Connolly C, Chopra V, Low C, Moniot S, Sapp E, Tousley AR, Vodicka P, Van Kanegan MJ, Kaltenbach LS, Crawford LA, Fuszard M, Higgins M, Miller JRC, Farmer RE, Potluri V, Samajdar S, Meisel L, Zhang N, Snyder A, Stein R, Hersch SM, Ellerby LM, Weerapana E, Schwarzschild MA, Steegborn C, Leavitt BR, Degterev A, Tabrizi SJ, Lo DC, DiFiglia M, Thompson LM, Dinkova-Kostova AT, Kazantsev AG.

Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4676-E4685. doi: 10.1073/pnas.1614943114. Epub 2017 May 22.

25.

Red hair, MC1R variants, and risk for Parkinson's disease - a meta-analysis.

Chen X, Feng D, Schwarzschild MA, Gao X.

Ann Clin Transl Neurol. 2017 Feb 24;4(3):212-216. doi: 10.1002/acn3.381. eCollection 2017 Mar.

26.

Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.

Espay AJ, Schwarzschild MA, Tanner CM, Fernandez HH, Simon DK, Leverenz JB, Merola A, Chen-Plotkin A, Brundin P, Kauffman MA, Erro R, Kieburtz K, Woo D, Macklin EA, Standaert DG, Lang AE.

Mov Disord. 2017 Mar;32(3):319-324. doi: 10.1002/mds.26913. Epub 2017 Feb 24. Review.

27.

Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects?

Schwarzschild MA.

J Parkinsons Dis. 2017;7(1):79-80. doi: 10.3233/JPD-160975. No abstract available.

28.

The melanoma-linked "redhead" MC1R influences dopaminergic neuron survival.

Chen X, Chen H, Cai W, Maguire M, Ya B, Zuo F, Logan R, Li H, Robinson K, Vanderburg CR, Yu Y, Wang Y, Fisher DE, Schwarzschild MA.

Ann Neurol. 2017 Mar;81(3):395-406. doi: 10.1002/ana.24852. Epub 2017 Jan 23.

29.

Urate as a Marker of Risk and Progression of Neurodegenerative Disease.

Paganoni S, Schwarzschild MA.

Neurotherapeutics. 2017 Jan;14(1):148-153. doi: 10.1007/s13311-016-0497-4. Review.

30.

Intake of antioxidant vitamins and risk of Parkinson's disease.

Hughes KC, Gao X, Kim IY, Rimm EB, Wang M, Weisskopf MG, Schwarzschild MA, Ascherio A.

Mov Disord. 2016 Dec;31(12):1909-1914. doi: 10.1002/mds.26819. Epub 2016 Oct 27.

31.

The epidemiology of Parkinson's disease: risk factors and prevention.

Ascherio A, Schwarzschild MA.

Lancet Neurol. 2016 Nov;15(12):1257-1272. doi: 10.1016/S1474-4422(16)30230-7. Epub 2016 Oct 11. Review.

PMID:
27751556
32.

Serum urate at trial entry and ALS progression in EMPOWER.

O'Reilly ÉJ, Liu D, Johns DR, Cudkowicz ME, Paganoni S, Schwarzschild MA, Leitner M, Ascherio A.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1-2):120-125. doi: 10.1080/21678421.2016.1214733. Epub 2016 Sep 28.

33.

Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors.

Xu K, Di Luca DG, Orrú M, Xu Y, Chen JF, Schwarzschild MA.

Neuroscience. 2016 May 13;322:129-37. doi: 10.1016/j.neuroscience.2016.02.035. Epub 2016 Feb 22.

34.

Purines: forgotten mediators in traumatic brain injury.

Jackson EK, Boison D, Schwarzschild MA, Kochanek PM.

J Neurochem. 2016 Apr;137(2):142-53. doi: 10.1111/jnc.13551. Epub 2016 Feb 25. Review.

35.

Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease.

Bhattacharyya S, Bakshi R, Logan R, Ascherio A, Macklin EA, Schwarzschild MA.

Mov Disord. 2016 Mar;31(3):417-21. doi: 10.1002/mds.26483. Epub 2016 Jan 25.

PMID:
26805433
36.

Prospective study of plasma urate and risk of Parkinson disease in men and women.

Gao X, O'Reilly ÉJ, Schwarzschild MA, Ascherio A.

Neurology. 2016 Feb 9;86(6):520-6. doi: 10.1212/WNL.0000000000002351. Epub 2016 Jan 13.

37.

Neuroprotective effects of urate are mediated by augmenting astrocytic glutathione synthesis and release.

Bakshi R, Zhang H, Logan R, Joshi I, Xu Y, Chen X, Schwarzschild MA.

Neurobiol Dis. 2015 Oct;82:574-579. doi: 10.1016/j.nbd.2015.08.022. Epub 2015 Sep 1.

38.

Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease.

Locascio JJ, Eberly S, Liao Z, Liu G, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Dhima K, Hung AY, Flaherty AW, Schwarzschild MA, Hayes MT, Wills AM, Shivraj Sohur U, Mejia NI, Selkoe DJ, Oakes D, Shoulson I, Dong X, Marek K, Zheng B, Ivinson A, Hyman BT, Growdon JH, Sudarsky LR, Schlossmacher MG, Ravina B, Scherzer CR.

Brain. 2015 Sep;138(Pt 9):2659-71. doi: 10.1093/brain/awv202. Epub 2015 Jul 28.

39.

The sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson's disease but not amyotrophic lateral sclerosis and cerebral ischemia.

Chen X, Wales P, Quinti L, Zuo F, Moniot S, Herisson F, Rauf NA, Wang H, Silverman RB, Ayata C, Maxwell MM, Steegborn C, Schwarzschild MA, Outeiro TF, Kazantsev AG.

PLoS One. 2015 Jan 21;10(1):e0116919. doi: 10.1371/journal.pone.0116919. eCollection 2015.

40.

Particulate matter and risk of Parkinson disease in a large prospective study of women.

Palacios N, Fitzgerald KC, Hart JE, Weisskopf MG, Schwarzschild MA, Ascherio A, Laden F.

Environ Health. 2014 Oct 7;13:80. doi: 10.1186/1476-069X-13-80.

41.

Mendelian randomization of serum urate and parkinson disease progression.

Simon KC, Eberly S, Gao X, Oakes D, Tanner CM, Shoulson I, Fahn S, Schwarzschild MA, Ascherio A; Parkinson Study Group.

Ann Neurol. 2014 Dec;76(6):862-8. doi: 10.1002/ana.24281. Epub 2014 Oct 3.

42.

Urate and neuroprotection trials.

Schwarzschild MA, Macklin EA, Ascherio A; Parkinson Study Group SURE-PD Investigators.

Lancet Neurol. 2014 Aug;13(8):758. doi: 10.1016/S1474-4422(14)70138-3. No abstract available.

PMID:
25030508
43.

A prospective analysis of airborne metal exposures and risk of Parkinson disease in the nurses' health study cohort.

Palacios N, Fitzgerald K, Roberts AL, Hart JE, Weisskopf MG, Schwarzschild MA, Ascherio A, Laden F.

Environ Health Perspect. 2014 Sep;122(9):933-8. doi: 10.1289/ehp.1307218. Epub 2014 Jun 6.

44.

Protection by inosine in a cellular model of Parkinson's disease.

Cipriani S, Bakshi R, Schwarzschild MA.

Neuroscience. 2014 Aug 22;274:242-9. doi: 10.1016/j.neuroscience.2014.05.038. Epub 2014 May 29.

45.

Allopurinol reduces levels of urate and dopamine but not dopaminergic neurons in a dual pesticide model of Parkinson's disease.

Kachroo A, Schwarzschild MA.

Brain Res. 2014 May 14;1563:103-9. doi: 10.1016/j.brainres.2014.03.031. Epub 2014 Mar 26.

46.

Restless legs syndrome: an early clinical feature of Parkinson disease in men.

Wong JC, Li Y, Schwarzschild MA, Ascherio A, Gao X.

Sleep. 2014 Feb 1;37(2):369-72. doi: 10.5665/sleep.3416.

47.

Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell loss.

McFarland NR, Dimant H, Kibuuka L, Ebrahimi-Fakhari D, Desjardins CA, Danzer KM, Danzer M, Fan Z, Schwarzschild MA, Hirst W, McLean PJ.

PLoS One. 2014 Jan 20;9(1):e86048. doi: 10.1371/journal.pone.0086048. eCollection 2014.

48.

Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.

Parkinson Study Group SURE-PD Investigators, Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, Gartner M, Hung A, Bwala G, Lenehan R, Encarnacion E, Ainslie M, Castillo R, Togasaki D, Barles G, Friedman JH, Niles L, Carter JH, Murray M, Goetz CG, Jaglin J, Ahmed A, Russell DS, Cotto C, Goudreau JL, Russell D, Parashos SA, Ede P, Saint-Hilaire MH, Thomas CA, James R, Stacy MA, Johnson J, Gauger L, Antonelle de Marcaida J, Thurlow S, Isaacson SH, Carvajal L, Rao J, Cook M, Hope-Porche C, McClurg L, Grasso DL, Logan R, Orme C, Ross T, Brocht AF, Constantinescu R, Sharma S, Venuto C, Weber J, Eaton K.

JAMA Neurol. 2014 Feb;71(2):141-50. doi: 10.1001/jamaneurol.2013.5528.

49.

Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?

Hung AY, Schwarzschild MA.

Neurotherapeutics. 2014 Jan;11(1):34-46. doi: 10.1007/s13311-013-0239-9. Review.

50.

Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study.

Ding H, Dhima K, Lockhart KC, Locascio JJ, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Hayes MT, Sohur US, Wills AM, Mollenhauer B, Flaherty AW, Hung AY, Mejia N, Khurana V, Gomperts SN, Selkoe DJ, Schwarzschild MA, Schlossmacher MG, Hyman BT, Sudarsky LR, Growdon JH, Scherzer CR.

Neurology. 2013 Oct 22;81(17):1531-7. doi: 10.1212/WNL.0b013e3182a95818. Epub 2013 Sep 25.

Supplemental Content

Loading ...
Support Center